Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database

Home Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database

Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database

Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database

/ Publications

Share the Post

About the Author

Related Posts

nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Comments

Comments are closed.